Minyue Zhang

Prof. Minyue Zhang


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2020 in Food Chemistry
Verified
Journal Article
Closed access
RLRuifeng Luo
Ruifeng Luo
MLMeisi Lin
Meisi Lin
CZChen Zhang
Chen Zhang
JSJinfeng Shi
Jinfeng Shi
SZSiyuan Zhang
Siyuan Zhang
FGFEI GAO
FEI GAO

8 November 2022 in Carbohydrate Polymers
Verified
Journal Article
Closed access
HXHaiting Xu
Haiting Xu
WNWenbiao Nie
Wenbiao Nie
LDLinxin Dai
Linxin Dai
RLRuifeng Luo
Ruifeng Luo
DLDasheng Lin
Dasheng Lin
FGFEI GAO
FEI GAO

15 October 2022 in BMC Cancer
Verified
Journal Article
Open access
PDF file
MLMei-Si Lin
Mei-Si Lin
HZHui-Yun Zhong
Hui-Yun Zhong
RYRita Lok-Hay Yim
Rita Lok-Hay Yim
QCQi-Yan Chen
Qi-Yan Chen
HDHong-Ling Du
Hong-Ling Du
MZMinyue Zhang
Minyue Zhang
Background: Tumor necrosis factor alpha-induced protein 2 (TNFAIP2), a TNFα-inducible gene, appears to participate in inflammation, immune response, hematopoiesis, and carcinogenesis. However, the potential role ofTNFAIP2in the development of acute myeloid leukemia (AML) remains unknow yet. Therefore, we aimed to study the biological role ofTNFAIP2in leukemogenesis.Methods: TNFAIP2mRNA level, prognostic value, co-expressed genes, differentially expressed genes, DNA methylation, and functional enrichment analysis in AML patients were explored via multiple public databases, including UALCAN, GTEx portal, Timer 2.0, LinkedOmics, SMART, MethSurv, Metascape, GSEA and String databases. Data from The Cancer Genome Atlas (TCGA), Gene Expression Omnibus (GEO) and Beat AML database were used to determine the associations betweenTNFAIP2expression and various clinical or genetic parameters of AML patients. Moreover, the biological functions ofTNFAIP2in AML were investigated through in vitro experiments.Results: By large-scale data mining, our study indicated thatTNFAIP2was differentially expressed across different normal and tumor tissues.TNFAIP2expression was significantly increased in AML, particularly in French–American–British (FAB) classification M4/M5 patients, compared with corresponding control tissues. Overexpression ofTNFAIP2was an independent poor prognostic factor of overall survival (OS) and was associated with unfavorable cytogenetic risk and gene mutations in AML patients. DNA hypermethylation ofTNFAIP2at gene body linked to upregulation ofTNFAIP2and inferior OS in AML. Functional enrichment analysis indicated immunomodulation function and inflammation response ofTNFAIP2in leukemogenesis. Finally, the suppression ofTNFAIPresulted in inhibition of proliferation by altering cell-cycle progression and increase of cell death by promoting early and late apoptosis in THP-1 and U937AML cells.Conclusion: Collectively, the oncogenicTNFAIP2can function as a novel biomarker and prognostic factor in AML patients. The immunoregulation function ofTNFAIP2warrants further validation in AML.

1 April 2025 in Advanced Science
Verified
Journal Article
Open access
BCBinzhen Chen
Binzhen Chen
JLJia Liu
Jia Liu
YZYaoxin Zhang
Yaoxin Zhang
CSChangming Shi
Changming Shi
DZDi Zhu
Di Zhu
JHJian Hou
Jian Hou
Multiple myeloma (MM) remains an incurable disease primarily due to the emergence of drug resistance, and the underlying mechanisms remain unclear. Extrachromosomal circular DNAs (eccDNAs) are prevalent in cancer genomes of both coding and non‐coding regions. However, the role of non‐coding eccDNA regions that serve as enhancers has been largely overlooked. Here, genome‐wide profiling of serum eccDNAs from donors and MM patients who responded well or poorly to bortezomib‐lenalidomide‐dexamethasone (VRd) therapy is characterized. A high copy number of eccDNA ANKRD28 (eccANKRD28) predicts poor therapy response and prognosis but enhanced transcriptional activity. Established VRd‐resistant MM cell lines exhibit a higher abundance of eccANKRD28, and CRISPR/Cas9‐mediated elevation of eccANKRD28 desensitizes bortezomib and lenalidomide treatment both in vitro and in vivo. Integrated multi‐omics analysis (H3K27ac ChIP‐seq, scRNA‐seq, scATAC‐seq, CUT&Tag, et al.) identifies eccANKRD28 as an active enhancer involved in drug resistance driven by the key transcription factor, POU class 2 homeobox 2 (POU2F2). POU2F2 interacts with sequence‐specific eccANKRD28 as well as RUNX1 and RUNX2 motifs to form the protein complex, which activates the promoter of oncogenes, including IRF4, JUNB, IKZF3, RUNX3, and BCL2. This study elucidates the potential transcriptional network of enhancer eccANKRD28 in MM drug resistance from a previously unrecognized epigenetic perspective.

10 November 2021 in Cancer Cell International
Verified
Journal Article
Open access
PDF file
FGFei Gao
Fei Gao
MLMei-Si Lin
Mei-Si Lin
YSYoujie Shu
Youjie Shu
MZMinyue Zhang
Minyue Zhang
LCLong Cheng
Long Cheng
QCQi-Yan Chen
Qi-Yan Chen
Background: High-dose melphalan (HDMEL, 200 mg/m2) is considered as the standard conditioning regimen for autologous hematopoietic stem cell transplantation (auto-HSCT) in multiple myeloma (MM). However, whether the combination of melphalan with busulfan (BUMEL) conditioning outperforms HDMEL remains controversy. Accordingly, a systematic review and meta-analysis was carried out to compare the outcomes of HDMEL and BUMEL-based conditioning regimens in newly diagnosed MM patients having undergone auto-HSCT. Methods: A systematic literature search was conducted in PubMed, Embase and Cochrane Library database until July 31, 2021, to identify all eligible studies comparing progression-free survival (PFS), overall survival (OS), optimal treatment response after auto-HSCT, duration of stem cell engraftment and incidence of toxic events between patients undergoing BUMEL-based and HDMEL conditioning regimens. Hazard ratio (HR), mean difference (MD) or odds ratio (OR) corresponding to 95% confidence interval (CI) were determined to estimate outcomes applying RevMan 5.4 software. Publication biases were assessed by performing Egger’s test and Begg’s test by Stata 15 software. Results: Ten studies with a total of 2855 MM patients were covered in the current meta-analysis. The results of this study demonstrated that patients having received BUMEL-based regimen was correlated with longer PFS (HR 0.77; 95% CI 0.67~0.89, P = 0.0002) but similar OS (HR 1.08; 95% CI 0.92~1.26, P = 0.35) compared with those having received HDMEL. The differences of best treatment response after auto-HSCT and duration of neutrophil or platelet engraftment did not have statistical significance between the two groups of patients. With respect to adverse effects, the patients in BUMEL-based group were less frequently subject to gastrointestinal toxicity while the patients in HDMEL group less often experienced mucositis and infection. No significant difference was observed in hepatic toxicity between the two groups of patients. Conclusions: In the present study, BUMEL-based conditioning was identified as a favorable regimen for a better PFS and equivalent OS as compared with HDMEL, which should be balanced against higher incidences of mucositis and infection. BUMEL-based conditioning is likely to act as an alternative strategy to more effectively improve auto-HSCT outcomes in MM.

11 January 2022 in Genes
Verified
Journal Article
Open access
PDF file
MZMinyue Zhang
Minyue Zhang
George CalinGeorge Calin
George Calin
MDMingdan Deng
Mingdan Deng
RARex K. H. Au-Yeung
Rex K. H. Au-Yeung
LWLu-Qian Wang
Lu-Qian Wang
CCChor Sang Chim
Chor Sang Chim
The long non-coding RNA (lncRNA) NKILA, localized to 20q13.31, is a negative regulator of NF-κB signaling implicated in carcinogenesis. As a CpG island is embedded in the promoter region of NKILA, it is hypothesized as a tumor suppressor lncRNA silenced by promoter DNA methylation in non-Hodgkin’s lymphoma (NHL). By pyrosequencing-verified methylation-specific PCR, NKILA methylation was detected in 1/10 (10%) NHL cell lines, but not in normal peripheral blood buffy coats or tonsils. NKILA methylation correlated with the repression of NKILA in cell lines. Hypomethylation treatment with 5-Aza-2′-deoxycytidine resulted in promoter demethylation and the re-expression of NKILA. In 102 NHL primary samples, NKILA was methylated in 29 (51.79%) diffuse large B-cell lymphoma (DLBCL) and 4 (20%) peripheral T-cell lymphoma cases, but unmethylated in all 26 mantle cell lymphoma cases. Mechanistically, the knockdown of NKILA resulted in promoting IkBα phosphorylation, associated with nucleus translocation of total p65 and phosphorylated p65 in SU-DHL-1 cells, hence constitutive NF-κB activation. Functionally, the knockdown of NKILA in SU-DHL-1 cells led to decreased cell death and increased cellular proliferation. Collectively, NKILA was a tumor suppressor lncRNA frequently hypermethylated in DLBCL. Promoter DNA methylation-mediated NKILA silencing resulted in increased cellular proliferation and decreased cell death via the repression of NF-κB signaling in NHL.